Abstract
The embryonic phenotype transformation of cardiomyocytes is an important characteristic of pathological cardiac hypertrophy. It includes transcriptional reprogramming of gene expression, a switch from lipid metabolism to carbohydrate metabolism, and a shift from α-myosin heavy chain (MHC) to fetal ß-MHC expression. The embryonic and adult cardiacmyocytes have distinct gene expression profiles. A series of genes that are expressed in embryos are later shut down after birth through the inhibition of endogenous constitutively activated molecules. These genes can be reactivated if these inhibitors are inactivated or downregulated, as occurs under certain pathological conditions. This promotes pathological cardiac hypertrophy. In this review, we list a class of endogenous molecules whose expression is inactivated during cardiac hypertrophy. They play a positive role in inhibition of the occurrence and development of cardiac hypertrophy and constitute the first natural line of defense against pathological cardiac hypertrophy.
Keywords: Cardiac hypertrophy, expression, first line of defense, inhibitors
Current Molecular Medicine
Title:The First Line of Defense Against Cardiac Hypertrophy
Volume: 13 Issue: 4
Author(s): X. Fan and X. Wu
Affiliation:
Keywords: Cardiac hypertrophy, expression, first line of defense, inhibitors
Abstract: The embryonic phenotype transformation of cardiomyocytes is an important characteristic of pathological cardiac hypertrophy. It includes transcriptional reprogramming of gene expression, a switch from lipid metabolism to carbohydrate metabolism, and a shift from α-myosin heavy chain (MHC) to fetal ß-MHC expression. The embryonic and adult cardiacmyocytes have distinct gene expression profiles. A series of genes that are expressed in embryos are later shut down after birth through the inhibition of endogenous constitutively activated molecules. These genes can be reactivated if these inhibitors are inactivated or downregulated, as occurs under certain pathological conditions. This promotes pathological cardiac hypertrophy. In this review, we list a class of endogenous molecules whose expression is inactivated during cardiac hypertrophy. They play a positive role in inhibition of the occurrence and development of cardiac hypertrophy and constitute the first natural line of defense against pathological cardiac hypertrophy.
Export Options
About this article
Cite this article as:
Fan X. and Wu X., The First Line of Defense Against Cardiac Hypertrophy, Current Molecular Medicine 2013; 13(4) . https://dx.doi.org/10.2174/1566524011313040015
DOI https://dx.doi.org/10.2174/1566524011313040015 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews The Ryanodine Receptor: A Pivotal Ca2+ Regulatory Protein and Potential Therapeutic Drug Target
Current Drug Targets Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Targeting SUMOylation Cascade for Diabetes Management
Current Drug Targets Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Current Pharmaceutical Design CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Skeletal Myoblasts for Heart Regeneration and Repair: State of the Art and Perspectives on the Mechanisms for Functional Cardiac Benefits
Current Pharmaceutical Design Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Ryanodine Receptor as Insecticide Target
Current Pharmaceutical Design Epigenetic Regulation of Myocardial Homeostasis, Self-Regeneration and Senescence
Current Drug Targets Extranuclear Localization of SIRT1 and PGC-1α: An Insight into Possible Roles in Diseases Associated with Mitochondrial Dysfunction
Current Molecular Medicine Diagnostic Approach to Mitochondrial Disorders: the Need for a Reliable Biomarker
Current Molecular Medicine Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry